Maria F. Camargo

Maria F. Camargo

Auto-generated profile, based on publicly available information

Maria F. Camargo

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil Advani
Sunil Advani
The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy. Molecular targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue. Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chemically amenable to antibody conjugation. To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody–drug conjugates of two auristatin derivatives with ionizing radiation. Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization. However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G2–M. Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE. In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE. Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts. In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody–drug conjugate technology.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
Antibody conjugation to drug and Cy5.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
Pertuzumab conjugated MMAE and IR tumor control.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
Pertuzumab conjugated MMAE and IR tumor control.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
T-MMAE stability and bystander cytotoxicity in HER2 negative cells.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
MMAF anti-HER2 antibody conjugates increase tumor G2/M fraction.